EMA: We're firmly convinced of the benefits of the Astrazeneca vaccine

The EMA is investigating reports of blood clots following the Astrazeneca vaccine, but does not change its recommendation.

Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750

BY RITZAU, TRANSLATED BY NIELSINE NIELSEN

Published: 17.03.21 at 12:03

The European Medicines Agency (EMA) remains "highly convinced" that the benefits of the Astrazeneca vaccine outweigh its risks, according to EMA Executive Director Emer Cooke at a Tuesday press conference.

"We are still firmly convinced that the benefits of the Astrazeneca vaccine in preventing Covid-19 with its associated risk of hospitalization and death outweigh the risk of these side effects," she says.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.